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The relationship between expression of the inhibitor of apoptosis protein survivin and the presence of high-risk human papillomavirus
(HPV) in oropharyngeal squamous cell carcinoma (OSCC) remains unclear. This also accounts for its role as a predictor of survival.
Therefore, we conducted a multicentre retrospective study on 106 consecutive oropharyngeal cancer patients. Human
papillomavirus sequences were detected by nested PCR protocols. Survivin and p16 expression as a surrogate marker for HPV
status were analysed by immunohistochemistry. Sequences of high-risk HPV were detected in 29% of cases. Prominent cytoplasmatic
expression of survivin was found in 58% of cases and nuclear expression of survivin was found in 19% of the survivin-positive
tumours. Nuclear expression of survivin was significantly correlated with HPV-negative tumours (P¼0.023) and with a poor disease-
free survival rate with an estimated 3-year disease-free survival probability of 35% for tumours with nuclear expression of survivin vs
78% for tumours with non-nuclear expression of survivin (hazard ratio¼8.264; 95% confidence interval (95% CI)¼2.510–27.210;
Po0.001). In multivariate analysis, p16 expression status as well as nuclear expression of survivin were strong independent and
opposing prognostic indicators of disease-free survival (hazard ratio¼0.068; 95% CI¼0.005–0.892; P¼0.041 and hazard
ratio¼15.975; 95% CI¼2.377–107.360; P¼0.004, respectively). Our data show that nuclear accumulation of survivin correlates
with HPV-independent carcinogenesis and is an independent predictor of poor survival in patients with OSCC.
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Currently, there are several studies suggesting that a subset of
oropharyngeal squamous cell carcinoma (OSCC) are associated with
oncogenic human papillomavirus (HPV) infection, in particular HPV
type 16 (Gillison and Lowy, 2004). These HPV-positive OSCC differ
from HPV-negative tumours in several biological and clinical aspects
including molecular alterations and prognosis (Klussmann et al,
2001; Smith et al, 2004) indicating that the former group represents
a separate tumour entity (Klussmann et al, 2003b). Recent studies
have reported that p16
INK4a expression is highly correlated with the
presence of HPV–DNA in OSCC (Hafkamp et al, 2003; Klussmann
et al, 2003a). The p16 protein is known to inactivate the function of
cdk4– and cdk6–cyclin D complexes. One of the critical substrates
of the G1-specific cdk–cyclin complexes is the retinoblastoma
(pRb)–E2F protein complex resulting in the release of E2F upon
phosphorylation (Sherr, 2001). Hence, p16 negatively regulates cell
proliferation by suppression of hyperphosphorylation of pRb
(Nobori et al, 1994). pRb also acts as a negative regulator of p16
expression (Li et al, 1994). Functional loss of p16 has been
demonstrated in a wide variety of other tumours (Roussel, 1999).
In HPV-associated carcinomas, p16 inactivation is rarely observed
because the viral oncoprotein E7 inactivates the pRb protein, which
is known to inhibit p16 transcription (Kim et al,1 9 9 8 ) .T h ep r e s e n c e
of HPV and the overexpression of p16 as a surrogate marker for
HPV-positive carcinomas has been associated with a favourable
prognosis in several studies (Ritchie et al, 2003; Reimers et al, 2007)
and HPV-associated OSCC have also been attributed to a higher
sensitivity to radiation therapy (Lindel et al, 2001).
Survivin, a recently characterised novel member of the inhibitor
of apoptosis family, is a bifunctional protein that acts as a
suppressor of apoptosis and plays a central role in cell division.
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sSurvivin has raised enormous interest in cancer research not only
because it is often upregulated in malignant lesions but also
because of the potential exploitation of its pathways in cancer
diagnosis and therapy (Li and Ling, 2006). Its overexpression has
been correlated with poor prognosis, cancer progression and drug
resistance (Li and Ling, 2006). Recent reports could show a
negative impact of survivin expression on survival in squamous
cell carcinoma of the oral cavity (Lin et al, 2005; Lo Muzio et al,
2005). However, one study reported a conflicting result with
increased overall survival rates for tumours with high survivin
scores regardless of the different staining patterns such as nuclear
or cytoplasmatic reactivity (Freier et al, 2007). There are no reports
on the impact of nuclear expression of survivin on survival in
OSCC, but its expression in the cell nuclei was found to correlate
with a poor survival probability in oesophageal squamous cell
carcinoma and small cell lung cancer (Grabowski et al, 2003; Lu
et al, 2004). Moreover, recent reports found a direct relationship
between survivin expression and HPV presence in squamous cell
carcinomas, which suggests that HPV-associated carcinogenesis
may have an effect on regulating the levels of survivin expression
(Lo Muzio et al, 2004, 2005). It is well established that high-risk
HPV E6 proteins induce the proteosome-mediated degradation of
p53 and that the expression of p53 results in downregulation of
survivin promoter constructs. Therefore, it is suggested that the
transactivation effect of HPV16 E6 on survivin appears to be
mediated by the p53 degradation pathway (Mirza et al, 2002;
Borbely et al, 2006).
The aim of this study was to determine the survival impact of
cytoplasmic and nuclear survivin expression in OSCC. Further-
more, we aimed to show potential interferences of the HPV-
dependent carcinogenesis with cytoplasmic and nuclear survivin
staining patterns.
MATERIALS AND METHODS
Subjects and materials
In this multicentre study, we analysed formalin-fixed, paraffin-
embedded tissue from 106 consecutive patients with newly
diagnosed and histologically confirmed squamous cell carcinoma
of the oropharynx treated at the hospital of the University of
Cologne (n¼92) and at the University of Duesseldorf (n¼14)
between July 1998 and November 2005. Some of these cases were
subjects in previously published studies (Preuss et al, 2007;
Reimers et al, 2007). Patients’ ages ranged from 34 to 82 years
(mean age¼57 years) out of which 77 patients were males (73%)
and 29 were females (27%). Written informed consent was
obtained from each patient and the scientific protocol
was approved by the Local Ethics Committee. Tumour staging
was assessed according to the 2002 American Joint Committee on
Cancer staging criteria (Greene et al, 2002). Details of the included
patients and tissues are presented in Table 1. The majority of the
patients underwent a multimodal treatment approach described in
detail previously (Preuss et al, 2007). Follow-up data were collected
at periodic visits in intervals of 4–6 months at our outpatients
department. Follow-up time was defined as the time from the date
of the diagnosis to the date of the last visit or the date of death. The
mean follow-up time was 20.3 months with a minimum of 0.33
months and a maximum of 79.8 months (median¼17.2 months).
Tumour specimens of all cases were obtained during surgery and
the tissue was fixed in 4% buffered-formalin and embedded in
paraffin by routine procedures.
All experiments were performed at the University Hospital of
Cologne. Slides from all blocks were reviewed by one pathologist
(UD) to select representative areas of the tumours for further
processing and immunohistochemistry. The criteria for block
selection were vital tumour tissue without necrosis and the
presence of a front of invasion. Only blocks with estimates of at
least 70% tumour cells were included.
Sample preparation, PCR and HPV typing
Tissues were processed as described previously (Klussmann et al,
2001). After confirming integrity of DNA by b-globin gene PCR,
HPV sequences were detected by highly sensitive nested PCR
protocols with degenerated primers A10/A5-A6/A8 for group A
(genital/mucosal) HPVs and CP62/70-CP65/69a for group B1
(cutaneous/EV) HPVs. PCR products (10ml) were separated in
2% agarose gels and were visualised by ethidium bromide staining.
Human papillomavirus typing was performed as described
previously (Klussmann et al, 2001).
Table 1 Clinicopathological characteristics of the patients
Characteristics No. of patients % N (total)
Sex 106
Male 77 73
Female 29 27
Age
Median 57
Range 35–83
T-stage 106
12 5 2 4
23 1 2 9
31 7 1 6
43 1 2 9
N-stage 105
01 8 1 7
12 1 2 0
2a 3 3
2b 30 28
2c 16 15
31 4 1 3
M-stage 103
09 5 9 2
18 8
Treatment 100
Surgery 76 76
Surgery+RT/RCT 55 55
RT/RCT alone 24 24
Survivin score 94
01 6 1 7
19 1 0
21 6 1 7
32 3 2 5
43 0 3 2
Survivin nuclear expression 94
+1 8 1 9
  76 81
p16 overexpression 101
+4 0 4 0
  61 60
HPV detection 102
+3 0 2 9
  72 71
RCT¼radiochemotherapy; RT¼radiotherapy.
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A total of 101 cases in the study group were eligible for the
immunohistochemical staining of p16. Formalin-fixed and
paraffin-embedded biopsy samples were processed by the
avidin–biotinylated–peroxidase complex method (Chem Mate
Detection kit; Dako Cytomation, Carpinteria, CA, USA). Sections
were deparaffinised by passage through xylene and rehydrated by a
graded series of ethanol, followed by microwave treatment for
antigen retrieval, which was for p16 staining two times for 7min at
600W in 10mM citrate buffer (pH 6.0). After a brief rinse with
Tris-buffer (BUF1), sections were incubated with the primary
antibody for 25min (p16: Ab-4, clone 16P04 Neo Markers,
Fremont, CA, USA). After another brief rinse with Tris-buffer,
the tissue was incubated with the biotinylated secondary antibody
for another 25min. After a brief rinse with Tris-buffer, the
endogenous peroxidase was inactivated with peroxidase-blocking
solution, 3 times for 2.5min each. After rinsing, the tissues were
incubated for another 25min with streptavidin conjugated with
horseradish peroxidase. Visualisation was performed three times
with 3-amino-9-ethylcarbazol (AEC; Dako Cytomation) for 5min,
and then sections were counterstained with haematoxylin. Non-
dysplastic peritonsillar squamous cell epithelium was used as a
negative control. p16 expression was classified according to a
previous publication (Reimers et al, 2007): strong nuclear staining
as well as strong cytoplasmic staining was considered positive for
p16 expression and it was regarded as overexpression if it was
strong and diffuse and more than 60% of the tumour cells were
p16-positive.
For survivin staining, tumour sections of 6mm were cut from
formalin-fixed, paraffin-embeded blocks and were mounted on
glass slides with silane-treated surface and were deparaffinised.
After antigen retrieval by heating in citrate buffer at 601Ci na n
incubator overnight these sections were treated with 3% H2O2 in
methanol for 20min to abolish endogenous peroxidase activity.
Then these sections were incubated with 2mgml
 1 anti-survivin
polyclonal rabbit (Novus Biologicals Inc., Littleton, CO, USA) at
41C over night. Biotinylated goat anti-rabbit immunoglobulin
(Dako) and streptavidin–horseradish peroxidase conjugate
(Amersham Biosciences, Buckinghamshire, UK) were applied at
room temperature. The sections were visualised using AEC
peroxidase substrate solution and haematoxylin counterstaining.
Negative control slides without primary antibody were included
for each tumour section. Cytoplasmic surviving staining levels
were determined according to Lo Muzio et al (2003): accordingly,
a mean percentage of cytoplasmic-positive tumour cells was
determined examining 300 cells in four areas at  400 magnifica-
tion. The tumours were assigned to one of the following categories:
score 0, o5%; score 1, 5–25%; score 2, 26–50%; score 3, 51–75%;
score 4475%. Slides were considered to be nuclear positive when
more than 5% of all tumour cell nuclei were stained regardless of
the cytoplasmic staining levels.
Analysis of the slides was performed in a blinded fashion by two
authors (UD and SP).
Statistical analysis
Survivin, p16 and HPV status were analysed using cross-
tabulations and w
2-test with the SPSS Base System, version 11.0
(SPSS, Chicago, IL, USA). Disease-free survival and overall survival
rates were estimated using the Kaplan–Meier algorithm for
incomplete observations. The overall survival time was defined
as the interval between the date of diagnosis and the last date when
the patient was known to be alive (censored) or date of death for
any reason (uncensored). The disease-free survival rate was
measured as the period between the date of diagnosis and the
date of the last follow-up examination in which the patient was
disease-free (censored), or the date of first recurrence irrespective
of local, regional or distant presentation (uncensored). Univariate
analysis of the various variables was performed with the log-rank
test. A Cox proportional hazards ratio model was used to
determine independent predictors of overall survival using factors
significant on univariate analysis as covariates. A P-value of less
than 0.05 was considered significant.
RESULTS
HPV status and HPV typing
Sequences of high-risk HPV were detected in DNA preparations
for 30 (29%) out of 102 OSCC cases, the DNA integrity of which
was sufficient. These included HPV16 in 29 (97%) cases and
HPV33 in 1 case.
Expression of p16
There were three different immunostaining patterns observed for
p16 immunoreactivity, that is, strong and diffuse cytoplasmic and
nuclear overexpression, weak cytoplasmic and nuclear staining
and no staining for all tumour cells. In general, surrounding
mesenchymal cells showed no p16 immunoreactivity, except for
some weak staining found occasionally in lymphocytes and
salivary glands. Nondysplastic squamous cell epithelium was
always p16-negative and served as an internal-negative control.
Overexpression of p16 was shown by 40% of all cases.
Expression of cytoplasmic and nuclear survivin
We found a negative survivin score in 17% of all cases, score 1 in
10%, score 2 in 17%, score 3 in 25% and score 4 in 32% of all cases.
In most OSCC, we found a homogeneous staining pattern
throughout the entire specimen. Cytoplasmic expression of
survivin (Figure 1A) was found in 83% of all cases. We found
AB
Figure 1 (A) Survivin expression in representative examples of OSCC, demonstrating strong and granular cytoplasmic staining (magnification  400).
(B) Distinct nuclear expression of survivin with concomitant weak cytoplasmic staining (magnification  400).
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sthat either there was no/sporadic nuclear staining or a distinct
staining intensity in more than 5% of all tumour cell nuclei
regardless of the cytoplasmic-staining levels. According to the
chosen cutoff point at 5%, 19% of all cases were classified as
nuclear surviving-positive (Figure 1B).
There was no significant interobserver variability in the blinded
analysis of the slides.
Correlation of HPV status, p16, cytoplasmic and nuclear
survivin expression
The correlation between p16 overexpression and the prevalence of
oncogenic HPV–DNA in the tumour cells was highly significant
(Po0.001). There was a significant correlation of higher cytoplasmic
survivin scores in p16-negative tumours (P¼0.0022). Nuclear
expression of survivin was significantly correlated with HPV-
negative tumours (P¼0.023). There was a higher proportion of
tumours with high levels of cytoplasmic survivin expression in the
HPV-negative cases (P¼0.022). There was no significant correla-
tion of cytoplasmic survivin expression levels, positive nuclear
survivin staining and p16 expression with the clinical staging
variables T, N, M and tumour grading.
Survival analysis
Human papillomavirus-positive tumours showed a tendency
towards a better 5-year disease-free survival rate compared with
the HPV-negative group (hazard ratio¼0.173; 95% confidence
interval (95% CI)¼0.022–1.344; P¼0.0576). The 5-year overall
survival probability of HPV-positive tumours was 72%, compared
with 48% for HPV-negative tumours, which was not significant
(P¼0.132). Patients with p16 overexpression in their tumours had
a significantly better 3-year disease-free survival probability
with 93.3 vs 58.4% for p16-negative cases (Figure 2A) and a better
5-year disease-free survival rate, namely, 93% compared with 44%
for patients with p16-negative tumours (hazard ratio¼0.115; 95%
CI¼0.015–0.900; P¼0.013). Patients with p16-positive OSCC had
a significantly better overall survival rate than those with p16-
negative tumours with a 5-year overall survival probability of 78 vs
43% (hazard ratio¼0.414; 95% CI¼0.187–0.915; P¼0.0244).
Higher cytoplasmic survivin expression levels were significantly
associated with a poorer 5-year disease-free survival rate (hazard
ratio¼2.114; 95% CI¼1.131–3.952; P¼0.0387). Nuclear expression
of survivin was strongly associated with an unfavourable disease-
free survival rate (Figure 2B) with an estimated 3-year disease-free
survival probability for OSCC exhibiting non-nuclear vs nuclear
survivin expression of 78 vs 35% (hazard ratio¼8.264; 95%
CI¼2.510–27.210; Po0.001). This correlation was found in HPV-
negative tumours (hazard ratio¼7.047; 95% CI¼1.998–24.848;
P¼0.0005). In the HPV-positive tumours the same correlation was
found with only one nuclear surviving-positive case in this
subgroup (P¼0.027).
Mulitvariate analysis of prognostic factors
Using the Cox proportional hazards model, we performed a
multivariate analysis to assess the independent predictive value of
all significant markers in overall- and disease-free survival, that is,
nuclear survivin staining and p16 expression and TNM stage.
p16 expression as well as nuclear expression of survivin were
independent and significant prognostic factors for disease-free
survival in this model (hazard ratio¼0.068; 95% CI¼0.005–0.892;
P¼0.041 and hazard ratio¼15.975; 95% CI¼2.377–107.360;
P¼0.004, respectively). The overall survival probability was
significantly affected by the factors p16 expression status and M
stage (hazard ratio¼0.309; 95% CI¼0.113–0.848; P¼0.023 and
hazard ratio¼8.040; 95% CI¼2.763–23.391; P¼0.0001, respectively).
DISCUSSION
Previous studies have shown that at least one-third of OSCC are
infected by oncogenic HPV, predominantly HPV type 16 and a
large meta-analysis showed a proportion of HPV-positive OSCC of
36.6% (Kreimer et al, 2005). We found HPV-positive OSCC in 29%
of our patients which is in line with a previous publication of our
group (Reimers et al, 2007). The slightly lower rate as compared to
other studies might be the result of different socio-economic
profiles and risk factors of the patients. Several studies showed a
distinct biological behaviour of the HPV-positive subset of
oropharyngeal tumours, resulting in a more favourable prognosis
(Li et al, 2003). Recently, the specific T-cell response to HPV16 E7
epitopes in subjects with HPV16 E7 expression and p16-positive
OSCC was shown (Hoffmann et al, 2006). p16 upregulation is also
present in HPV-related uterine cervical lesions, and it is likely that
p16 is upregulated in HPV-positive tumours due to the interaction
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Figure 2 (A) Univariate survival analysis by p16 tumour status. Kaplan–Meier survival curves for the estimated 3-year disease-free survival probability of
93 vs 58%, respectively (hazard ratio¼0.115; 95% CI¼0.015–0.900; P¼0.013). (B) Univariate survival analysis by nuclear expression for survivin. Kaplan–
Meier survival curves for the estimated 3-year disease-free survival probability of 78 vs 35%, respectively (hazard ratio¼8.264; 95% CI¼2.510–27.210;
Po0.001).
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sof the HPV16 E7 oncogene product with the pRb protein. This
suggests that p16 overexpression is most likely the result of
transcriptionally active HPV infection and in previous studies, p16
expression was highly correlated with the HPV status in OSCC
(Klussmann et al, 2003a). In line with this, we found that p16
overexpression was highly correlated with the presence of HPV–
DNA in this series of OSCC (Po0.0001). p16 overexpression was
an independent indicator of a favourable disease-free survival,
which is in line with other reports (Mellin et al, 2000).
Targeting survivin may provide a novel perspective in cancer
therapy by simultaneously disabling multiple signalling circuitries.
Currently, several clinical trials targeting survivin with various
approaches ranging from immunotherapy to antagonists are under
way and might be broadly applicable to different tumours (Altieri,
2006). High levels of cytoplasmic survivin expression have been
reported previously in OSCC (Weinman et al, 2003) with similar
staining patterns as shown in our study in which 58% of all
tumours prominently expressed survivin in the cytoplasm.
Here, we found a significantly inverse correlation between
cytoplasmic survivin expression and HPV-associated carcinomas.
Human papillomavirus-positive tumours and p16 overexpression
were significantly associated with lower scores for cytoplasmic
survivin expression (P¼0.028 and P¼0.022, respectively). Cell
culture experiments suggest that expression of high-risk HPV E6
proteins lead to survivin overexpression by the proteosome-
mediated degradation of p53, which inhibits p53-mediated
downregulation of survivin promotor constructs (Munger and
Howley, 2002). However, inactivation of p53 has not only been
found in HPV-associated carcinoma but also in almost all OSCC.
In fact, in the carcinogenesis driven by environmental toxins such
as tobacco and alcohol, p53 mutations are more frequently found
with subsequent deletion of p53 (Balz et al, 2003). Moreover,
biallelic loss of the gene or transcriptional silencing of p53,
both of which have been reported in OSCC cell lines, results in a
complete loss of transcript in tumour cells (Hauser et al, 2002).
These findings might explain the positive correlation of cytoplas-
mic survivin overexpression and HPV-negative tumours in our
series.
Survivin overexpression has been shown to be related to a poor
survival probability in squamous cell carcinomas of the oral cavity
(Lo Muzio et al, 2005). However, in a recent paper the contrary
finding that high survivin expression levels predict a favourable
overall survival in oral squamous cell carcinoma was reported.
This was most distinctly found in patients who were treated with
radiotherapy. Therefore, the authors concluded that survivin
expression might be used as a marker to predict the response to
radiotherapy (Freier et al, 2007). In our series, cytoplasmic
survivin overexpression was significantly correlated with poor
disease-free survival rates in univariate analyses. However, the
subgroup of patients that received primary radiotherapy was too
small for statistical evaluation of differences in survival probabil-
ities. In line with several studies, we found that in OSCC, survivin
exists in two subcellular pools, that is, cytoplasmatic and nuclear.
All tumours with immunoreactivity for survivin showed cytoplasmic
expression and 19% showed nuclear expression of survivin. As
survivin mediates the regulation of both cell viability and cell
division, the nuclear pool of survivin is likely to be involved in
promoting cell proliferation, whereas the cytoplasmic pool of
survivin may participate in controlling cell survival (Li, 2003).
However, the molecular mechanisms underlying nuclear survivin
expression in tumours are not entirely understood. Active nuclear
import is mediated by nuclear localisation signals (NLS), which
interact with import receptors (Weis, 2003). Mutations in the NLS
or enhanced binding to nuclear components may account for
pronounced nuclear survivin (Engels et al, 2007). The nuclear
expression patterns of survivin were significantly correlated with
HPV-negative tumours in our series, which suggests that the HPV-
dependent carcinogenesis interferes with the active nuclear import
of survivin. Several studies found that nuclear expression of
survivin predicts poor survival probabilities in human cancer
(Grabowski et al, 2003; Lu et al, 2004) but this finding remains
controversial as papers on identical tumour entities show
correlation of nuclear survivin expression with a favourable
prognosis (Vischioni et al, 2004). So far, no study investigated
this correlation in OSCC. The nuclear expression of survivin in our
study strongly correlated with poor disease-free survival prob-
abilities in univariate as well as multivariate analyses (Po0.001
and P¼0.004, respectively). However, considering the short
follow-up time with a median of 17.2 months and the relatively
small number of patients in the nuclear surviving-positive group,
the significance of these results is somewhat limited.
In conclusion, our findings show an expression of survivin in
the majority of OSCC. The cytoplasmic and particularly the
nuclear survivin expression predict a poor survival outcome in
these patients. The survivin expression patterns seem to be
influenced by the different molecular pathways of carcinogenesis
and nuclear survivin expression seems to be increased in HPV-
negative tumours.
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